对比分析 FLOT 方案与 FOLFOX 方案治疗中晚期胃癌的近远期疗效 及对血清肿瘤标志物和 NRP-2 的影响. (Chinese)

Comparative Analysis of the Short-term and Long-term Efficacy of FLOT and FOLFOX in the Treatment of Advanced Gastric Cancer and Their Impact on Serum Tumor Markers and NRP-2. (English)

Objective: To compare the short-term and long-term efficacy of FLOT and FOLFOX in the treatment of advanced gastric cancer (GC), as well as their effects on serum tumor markers and NRP-2. Methods: 82 patients with advanced gastric cancer admitted to our hospital from March 2020 to February 2022 were selected and divided into FLOT group and FOLFOX group based on different chemotherapy methods, with 41 cases in each group. Compare the short-term and long-term efficacy, serum tumor markers and NRP-2 levels between two groups. Follow up until November 2023, record the survival status of two groups of patients and draw Kaplan-Meier survival curves. Results: The objective effective rate of FLOT group was higher than FOLFOX group (85.37% vs. 65.85%, P＜0.05) . The levels of serum carcinoembryonic antigen [ (12.77±1.85) ng/mL vs. (20.69±2.58) ng/mL], carbohydrate antigen 19-9 [ (20.46±5.20) U/m L vs. (29.41±8.04) U/m L], carbohydrate antigen 125 [ (14.90±5.61) U/m L vs. (20.72±6.23) ng/mL], and NRP-2 [ (13.01±2.11) ng/mL vs. (15.23 ±2.25) ng/mL] in the FLOT group were lower than the FOLFOX group after treatment, PFS [12.900 (95% CI:12.183～13.617) months vs. 9.600 (95% CI: 8.471～10.729) months] and OS [28.103 (95% CI: 25.209～30.996) months vs. 20.799 (95%CI: 18.482～23.115) months] were longer than the FOLFOX group (P＜0.05) . There was no difference in disease control rate and incidence of toxic side effects between the two groups (P＞0.05) . Conclusion: FLOT and FOLFOX are both effective chemotherapy regimens for mid to late stage GC, with consistent safety. However, the former has advantages in improving objective efficacy, reducing serum tumor markers and NRP-2 levels, and prolonging survival. [ABSTRACT FROM AUTHOR]

目的: 对比研究 FLOT 方案与 FOLFOX 方案治疗中晚期胃癌 (GC) 的近远期疗效及对血清肿瘤标志物和 NRP-2 的影响。方法: 选入我院2020年3月～2022 年 2 月收治的 82 例中晚期GC患者, 根据化疗方法不同分为FLOT组和 FOLFOX 组, 各 41 例。比较两组的近远期疗效、血清肿瘤标志物和 NRP-2 水平; 随访至2023年11月, 记录两组患者生存状态并绘制 Kaplan-Meier 生存曲线。结果: FLOT 组客观有效率显著高于FOLFOX 组 (85.37%vs. 65.85%,P＜0.05) 。FLOT组治疗后血清癌胚抗原[ (12.77±1.85) ng/m L vs. (20.69±2.58) ng/mL]、糖类抗原19-9[ (20.46±5.20) U/m L vs. (29.41±8.04) U/m L]、糖类抗原 125[ (14.90±5.61) U/m L vs. (20.72±6.23) ng/mL] 和 NRP-2 [ (13.01±2.11) ng/mL vs. (15.23±2.25) ng/mL]水平均显著低于 FOLFOX 组, PFS[12.900 (95%CI:12.183～13.617) 个月vs. 9.600 (95%CI:8.471～10.729) 个月]和 OS [28.103 (95%CI:25.209～30.996) 个月vs. 20.799 (95%CI:18.482～23.115) 个月]显著长于 FOLFOX 组 (P＜0.05) 。两组疾病控制率和毒副反应发生率无显著差异 (P＞0.05) 。结论: FLOT 方案和 FOLFOX 方案均是中晚期 GC 的有效化疗方案, 安全性一致, 但前者在提高客观有效率、降低血清肿瘤标志物和 NRP-2 水平、延长生存期方面更具优势。 [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)